Head-To-Head Contrast: Cynata Therapeutics (OTCMKTS:CYYNF) versus Entrada Therapeutics (NASDAQ:TRDA)

Entrada Therapeutics (NASDAQ:TRDA) and Cynata Therapeutics (OTCMKTS:CYYNF) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, risk, analyst recommendations, earnings and institutional ownership.

Institutional & Insider Ownership

86.4% of Entrada Therapeutics shares are owned by institutional investors. 8.1% of Entrada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Entrada Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the S&P 500. Comparatively, Cynata Therapeutics has a beta of -0.41, meaning that its share price is 141% less volatile than the S&P 500.

Profitability

This table compares Entrada Therapeutics and Cynata Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Entrada Therapeutics	-168.16%	-26.42%	-22.08%
Cynata Therapeutics	N/A	N/A	N/A

Earnings & Valuation

This table compares Entrada Therapeutics and Cynata Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entrada Therapeutics	$210.78 million	2.01	$65.63 million	($2.49)	-4.46
Cynata Therapeutics	N/A	N/A	N/A	N/A	N/A

Entrada Therapeutics has higher revenue and earnings than Cynata Therapeutics.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Entrada Therapeutics and Cynata Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entrada Therapeutics	1	1	1	0	2.00
Cynata Therapeutics	0	0	0	0	0.00

Entrada Therapeutics currently has a consensus target price of $16.50, indicating a potential upside of 48.65%. Given Entrada Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Entrada Therapeutics is more favorable than Cynata Therapeutics.

Summary

Entrada Therapeutics beats Cynata Therapeutics on 7 of the 10 factors compared between the two stocks.

About Entrada Therapeutics

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

About Cynata Therapeutics

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, brain cancer, sepsis, acute respiratory distress syndrome, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.